Evidence map›Paper›PMID 30478655›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2018

Correction to: A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets.

Yasamin Davatgaran Taghipour, Roodabeh Bahramsoltani, André M Marques, Rozita Naseri, Roja Rahimi, Pouya Haratipour, Amin Iranpanah, Mohammad Hosein Farzaei, Mohammad Abdollahi

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Oxidative medicine and cellular longevity · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Yasamin Davatgaran TaghipourDepartment of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Roodabeh BahramsoltaniPhytoPharmacology Interest Group (PPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
André M MarquesOswaldo Cruz Foundation (FIOCRUZ), Institute of Technology in Pharmaceuticals (Farmanguinhos), Rio de Janeiro, RJ, Brazil.
Rozita NaseriInternal Medicine Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Roja RahimiDepartment of Pharmacy in Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Pouya HaratipourDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Amin IranpanahFaculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Hosein FarzaeiPharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. mh.farzaei@gmail.com.
Mohammad AbdollahiToxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The corresponding author, Mohammad Hosein Farzaei, affiliation is Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. The correct spelling of the 7th author surname is Iranpanah.

Identifiers

PMID30478655
PMCPMC6279662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.